MCKESSON CORP SEC 10-Q Report

McKesson Corporation, a leading healthcare services and information technology company, has released its Form 10-Q report for the third quarter. The report provides a comprehensive overview of the company's financial performance and operational highlights, showcasing significant growth across various segments and strategic business initiatives.

Financial Highlights

• Revenues: $97,827 million, reflecting a significant increase from the previous year's $79,283 million, driven by growth across all segments.
• Gross Profit: $3,279 million, showing a slight increase from $3,152 million in the prior year, indicating improved cost management despite higher sales.
• Operating Income: $1,036 million, marginally up from $1,029 million, demonstrating stable operational efficiency.
• Net Income: $831 million, a decrease from $960 million, primarily due to higher income tax expenses.
• Net Income Attributable to McKesson Corporation: $784 million, down from $915 million, impacted by increased tax expenses and other income variations.
• Diluted EPS: $6.25, compared to $7.00 in the previous year, reflecting the decrease in net income.

Business Highlights

• U.S. Pharmaceutical Segment Performance: The U.S. Pharmaceutical segment experienced significant growth, driven by increased demand for branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs. This segment also benefited from enhanced practice management and technology solutions provided to community-based oncology and specialty practices.
• Prescription Technology Solutions (RxTS) Segment Performance: RxTS saw an increase in revenue, attributed to its role in addressing medication access, affordability, and adherence challenges. The segment's technology services, including electronic prior authorization and prescription price transparency, contributed to its growth.
• Medical-Surgical Solutions Segment Performance: The Medical-Surgical Solutions segment maintained stable performance, providing medical-surgical supply distribution and logistics services to healthcare providers. The segment's offerings include national brand products and McKesson's own line of products.
• International Segment Performance: The International segment, which includes operations in Canada and Norway, showed steady performance. The Canadian operations focus on delivering medicines and IT solutions, while the Norwegian operations provide distribution and retail services.
• Future Outlook for Medical-Surgical Solutions: The company announced its intention to separate the Medical-Surgical Solutions segment into an independent company, aiming to enhance focus and operational efficiency.
• Acquisition of PRISM Vision Holdings, LLC: McKesson completed the acquisition of a controlling interest in PRISM Vision Holdings, LLC, enhancing its U.S. Pharmaceutical segment with additional ophthalmology and retina management services.
• Acquisition of Community Oncology Revitalization Enterprise Ventures, LLC: The acquisition of a controlling interest in Core Ventures expanded McKesson's capabilities in providing business and administrative services to oncology practices, further strengthening the U.S. Pharmaceutical segment.
• Geographical Expansion: The company is evaluating the financial impact of its agreement to sell its retail and distribution businesses in Norway, indicating a strategic shift in its International segment operations.

SEC Filing: MCKESSON CORP [ MCK ] - 10-Q - Aug. 06, 2025